Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1

Interventions

olaparib 5Specimen Handling 4Magnetic Resonance Spectroscopy 4Cyclophosphamide 4fludarabine 3X-Rays 2Taxes 2Platinum 2Paclitaxel 2Oncolytic Virotherapy 2Letrozole 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorodeoxyglucose F18 2Doxorubicin 2Cytoreduction Surgical Procedures 2Cisplatin 2Carboplatin 2Aspirin 21,2-diaminocyclohexaneplatinum II citrate 2trastuzumab biosimilar HLX02 1sodium thiosulfate 1pertuzumab 1pembrolizumab 1palbociclib 1niraparib 1montelukast 1gallium 68 PSMA-11 1eribulin 1entrectinib 1cobimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Ovarian Neoplasms × Salpingo-oophorectomy × Clear all
NCT03382574 2022-06-14

Pilot Study of Denosumab in BRCA1/2 Mutation Carriers Scheduled for Risk-Reducing Salpingo-Oophorectomy

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Terminated
2 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡